Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Dissociative or Lysergamide

Use the filters below to narrow your results.

generic:
None (1) · 1B-LSD (1) · 1cP-LSD (1) · 1P-LSD (1) · 1V-LSD (1) · 2-FDCK (1) · 3-HO-PCE (1) · 3-HO-PCP (1) · 3-MeO-PCE (1) · 3-MeO-PCP (1) · 4-MeO-PCP (1) · AL-LAD (1) · ALD-52 (1) · Deschloroketamine (1) · Dextromethorphan (1) · Dextrorphan (1) · Diphenidine (1) · Ephenidine (1) · ETH-LAD (1) · Eticyclidine (1) · Ibogaine (1) · LSA (1) · LSD (1) · LSH (1) · LSZ (1) · Methoxetamine (1) · MiPLA (1) · Nitrous oxide (1) · O-PCE (1) · PRO-LAD (1) · Salvia divinorum (1) · Salvinorin A (1) · Xenon (1)
brand:
None (29) · Delysid (historical, Sandoz, withdrawn 1965) (1) · DXM (1) · DXO (1) · Spravato (1)
classes: (Click arrow to add another value)
mechanism:
None (1) · 1-acetyl-LSD; prodrug of LSD (1) · 5-HT2A agonist; D2 partial agonist (1) · 5-HT2A partial agonist (1) · Active metabolite of DXM; NMDA antagonist (1) · Contains salvinorin A (1) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · LSD analogue; 5-HT2A agonist (4) · Lysergic acid 2,4-dimethylazetidide; 5-HT2A agonist (1) · Lysergic acid hydroxyethylamide; 5-HT2A agonist (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) · Prodrug of LSD; 5-HT2A agonist (4)
uses:
None (32) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1)
starting dose:
None (32) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)
preparations:
None (32) · 28 mg/device (each dose uses 2 devices) (1)
fda max:
None (32) · 84 mg per session (1)
routes:
None (31) · Intranasal (under direct medical supervision) (1) · Oral (1)
onset:
None (31) · 30–60 minutes (1) · Within hours of first administration (1)
duration:
None (31) · 8–12 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)
halflife:
None (31) · 3–5 hours (1) · ~7-12 hours (1)
bioavailability:
None (31) · 70–90% (oral) (1) · ~48% intranasal (1)
pregnancy:
None (31) · Avoid; may cause fetal harm (1) · Not established (1)
legal:
None (31) · Rx, Schedule III (US). REMS program required. (1) · Schedule I (United States) (1)

Showing below up to 33 results in range #1 to #33.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"